No Detail Found!

Clinical outcomes of using second - versus first-Generation EGFR-tkis for the First-Line treatment of advanced NSCLC patients with EGFR mutations: A meta-analysis

Author(s)
Bing Hou Department of Thoracic Surgery, Xinqiao Hospital, Army Military Medical University (Third Military Medical University),Chongqing,China
Xiao Lu Department of Thoracic Surgery, Xinqiao Hospital, Army Military Medical University (Third Military Medical University),Chongqing,China
Dong-Cai Gao Department of Thoracic Surgery, Xinqiao Hospital, Army Military Medical University (Third Military Medical University),Chongqing,China
Quan-Xing Liu Department of Thoracic Surgery, Xinqiao Hospital, Army Military Medical University (Third Military Medical University),Chongqing,China
Dong Zhou Department of Thoracic Surgery, Xinqiao Hospital, Army Military Medical University (Third Military Medical University),Chongqing,China
Hong Zheng Department of Thoracic Surgery, Xinqiao Hospital, Army Military Medical University (Third Military Medical University),Chongqing,China
Ji-Gang Dai Department of Thoracic Surgery, Xinqiao Hospital, Army Military Medical University (Third Military Medical University),Chongqing,China
Abstract
First-generation EGFR-TKIs (gefitinib/erlotinib) and second-generation EGFR-TKI (afatinib) have become the current first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC), however, the effects of using second-generation EGFR-TKIs compared to those of using first-generation EGFR-TKIs as a first-line treatment for NSCLC patients with EGFR mutations remain unknown. We conducted this meta-analysis based on 4 retrospective and 2 randomized controlled studies published between 2016 and 2018. We surveyed the effectiveness of afatinib/dacomitinib and gefitinib/erlotinib as first-line treatments for stage III-IV EGFR-mutated NSCLC patients. The combined hazard ratio (HR) for the progression free survival (PFS) of second-generation EGFR-TKI group versus that first-generation drug group was 0.64 [95% confidence interval (95% CI) 0.55-0.74; P<0.001], demonstrating a superior PFS in the second-generation group. This outcome coincided with the subgroup analyses comparing the PFS of patients with EGFR exon 19 deletion (HR = 0.68 [95% CI 0.55-0.83; P = 0.0002]) or L858R mutation (HR = 0.64 [95% CI 0.510.81; p=0.0002]). Meanwhile, second-generation drugs could to significantly improve the time to progression (TTFs) compared to first-generation drugs (HR = 0.81 [95% CI 0.67-0.89; P = 0.03]). Afatinib and dacomitinib may be the superior first-line treatment for advanced NSCLC patients with EGFR mutations.
Publication Details
Page(s) 1459-1468
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: 4, Year: 2021

Request the full text from PASTIC

Keywords
Lung Cancer, EGFR mutation, EGFR-TKI, First-line treatment
0

Citations

0

Downloads

92

Views